Laboratory Co. of America (NYSE:LH) Given New $260.00 Price Target at Barclays

Laboratory Co. of America (NYSE:LH) had its price objective dropped by research analysts at Barclays from $271.00 to $260.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 5.61% from the stock’s current price.

LH has been the topic of several other reports. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Hsbc Global Res raised shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 30th. Jefferies Financial Group raised their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday. Robert W. Baird lifted their price target on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $263.77.

Laboratory Co. of America Stock Performance

NYSE:LH traded down $1.56 during mid-day trading on Friday, reaching $246.18. 588,360 shares of the company’s stock were exchanged, compared to its average volume of 613,994. Laboratory Co. of America has a one year low of $191.97 and a one year high of $258.59. The firm has a market capitalization of $20.59 billion, a PE ratio of 47.62, a price-to-earnings-growth ratio of 1.86 and a beta of 1.07. The business’s fifty day simple moving average is $236.56 and its two-hundred day simple moving average is $229.47. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. Analysts anticipate that Laboratory Co. of America will post 14.51 earnings per share for the current fiscal year.

Insider Transactions at Laboratory Co. of America

In other news, CEO Adam H. Schechter sold 6,189 shares of Laboratory Co. of America stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the completion of the sale, the chief executive officer now owns 87,441 shares in the company, valued at $21,289,260.27. The trade was a 6.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the sale, the director now owns 12,722 shares of the company’s stock, valued at $2,989,670. This represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,572 shares of company stock worth $5,915,209. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Laboratory Co. of America

Hedge funds and other institutional investors have recently bought and sold shares of the business. OneDigital Investment Advisors LLC grew its stake in shares of Laboratory Co. of America by 115.7% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company’s stock worth $1,361,000 after acquiring an additional 3,265 shares in the last quarter. Alexander Randolph Advisory Inc. bought a new stake in shares of Laboratory Co. of America in the 3rd quarter worth $955,000. Wealthcare Advisory Partners LLC grew its stake in shares of Laboratory Co. of America by 23.9% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company’s stock worth $583,000 after acquiring an additional 490 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in shares of Laboratory Co. of America in the 3rd quarter worth $2,316,000. Finally, Barclays PLC grew its stake in shares of Laboratory Co. of America by 11.8% in the 3rd quarter. Barclays PLC now owns 620,721 shares of the medical research company’s stock worth $138,718,000 after acquiring an additional 65,356 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.